In a recent legal victory for Bausch Health Companies Inc., the pharmaceutical giant has, for the time being, successfully overcome a proposed class action lawsuit that accused the company and its executives of misleading shareholders regarding potential threats to its financial stability. A federal judge in New Jersey determined that the complaint did not adequately identify any actionable misstatements or omissions, nor did it plausibly plead scienter, which refers to the intent or knowledge of wrongdoing, as required under securities fraud claims.
This judgment signifies a hurdle for the plaintiffs in proving their claims against Bausch Health, which has faced scrutiny over its financial reporting practices. For additional details on the case proceedings and the judge’s rationale behind the dismissal, refer to the full article on Law360.